EHD2 and neoplasm: Our IHC analyses demonstrated high cytoplasmic EHD2 expression in a substantial proportion of breast tumors, associated with shorter BC-specific patient survival (Figure 3B) and higher tumor grade (Supplementary file 1-Table 1).